The global dry powder inhaler device market size was USD 19.66 Billion in 2022 and is expected to register a revenue CAGR of 4% over the forecast period, according to the latest report by Reports and Data.
Manufacturers are continuously developing technologically advanced Dry Powder Inhaler (DPI) devices as more patients with respiratory disorders prefer practical and easy-to-use inhalers. DPIs are considered more convenient than traditional inhalers as they do not require propellants, making them less harmful to the environment. Furthermore, DPIs are preferred for the treatment of respiratory illnesses due to their superior ability to deliver dry powder medications directly to the lungs.
The government’s programs and funding for respiratory illness research are also likely to increase demand for DPI devices. For example, the National Institutes of Health (NIH) in the United States established the National Heart, Lung, and Blood Institute to support research on respiratory illnesses, which is expanding the usage of DPI devices in this region.
Furthermore, revenue growth in the worldwide dry powder inhaler device market is predicted to be driven by a growing need for personalized medicine and the development of cutting-edge drug formulations. DPI devices that can deliver diverse dry powder pharmaceutical formulations, including combination treatments, are being developed by manufacturers, which is increasing the use of DPI devices in the treatment of respiratory disorders.
Additionally, the revenue growth of the dry powder inhaler device market is increasing as a consequence of technological advancements and the introduction of smart DPI devices. Smart DPI devices feature sensors and can provide real-time feedback on patient adherence and medicine consumption, which should improve patient outcomes.
The U.S. Food and Drug Administration (FDA) asserts that dry powder inhalers are a secure, practical, and efficient method of administering painkillers to persons with asthma or other respiratory conditions.
For dry powder inhalers, the FDA has set minimum effectiveness and safety guidelines as well as labeling specifications for manufacturers.
In order to restrict ozone-depleting compounds in all goods that employ chlorofluorocarbons (CFCs) or hydrochlorofluorocarbons (HCFCs), the U.S. Environmental Protection Agency (EPA) has enacted rules.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1233
Some of the prominent players profiled in the global dry powder inhaler device market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Chiesi Farmaceutici S.p.A., Cipla Inc., 3M Company, Hovione, and DPI Co., Ltd.
Some Key Highlights from the Report
- In 2021, the multi-dose sector held a larger market revenue share compared to other inhaler device types. This is because patients prefer multi-dose inhaler devices due to their affordability and ease of use. These devices are designed to deliver multiple doses of medication from a single inhaler, eliminating the need for patients to carry around multiple inhalers or refill them frequently. Multi-dose inhaler devices also ensure consistent and effective medication administration to the lungs, making them a suitable treatment option for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The medication is aerosolized using a small propellant, ensuring accurate dosing and efficient pharmaceutical delivery to the lungs.
- In 2021, the COPD segment held the largest revenue share in the inhaler device market due to the increasing prevalence of this condition worldwide. COPD, characterized by blocked airways that cause difficulty in breathing, is becoming more prevalent due to factors such as an aging population and smoking. It is a leading cause of morbidity and mortality globally. Dry powder inhaler devices are considered one of the most effective treatment options for COPD. These devices deliver medication directly to the lungs, providing quick relief from symptoms. They are portable, do not require an external power source, and are easy to use. These factors have contributed to the significant revenue growth in the COPD segment of the market.
- The North American region is expected to dominate the market for DPI devices, exhibiting the largest market share. The demand for portable and user-friendly devices is projected to grow steadily during the forecast period, driving market growth. The region’s aging population and the increasing prevalence of respiratory conditions such as asthma and COPD are expected to contribute to market expansion. The market is also likely to benefit from the growing trend of self-medication and the preference for dry powder inhalers over conventional inhalers. Furthermore, the well-developed healthcare infrastructure in the region and government initiatives to promote respiratory health are expected to support the market’s expansion.
- GlaxoSmithKline plc announced a collaboration with Innoviva, Inc. in 2020 to develop and market its respiratory medication portfolio, which includes dry powder inhaler devices. The collaboration aims to increase both firms’ market presence and to research novel and innovative medicines for respiratory disorders.
- AstraZeneca plc announced in 2020 that it has acquired Pearl medicines Inc., a biopharmaceutical firm located in the United States that specializes in the development of inhaled medicines for respiratory illnesses. The purchase sought to broaden AstraZeneca’s respiratory portfolio and increase its foothold in the dry powder inhaler device market.
- GlaxoSmithKline plc: GlaxoSmithKline debuted its Ellipta® inhaler device in 2020, which is intended for the administration of its respiratory medications, including dry powder formulations. The device’s basic form and simple function make it a suitable choice for those suffering from respiratory disorders.
- Boehringer Ingelheim International GmbH: In 2020, Boehringer Ingelheim debuted their Respimat® inhaler device, which is designed to deliver its respiratory medicine portfolio, including dry powder formulations. The gadget has a unique inhalation mechanism that delivers a thin mist of medicine to the lungs, giving patients with respiratory disorders with quick and effective relief.
For the purpose of this report, Reports and Data has segmented the global dry powder inhaler device market on the basis of Type Outlook, Application Outlook, and Regional Outlook:
Type Outlook (Revenue, USD Billion; 2022 – 2032)
Application Outlook (Revenue, USD Billion; 2022 – 2032)
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- Rest of Europe
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
Request a customization on the report @ https://www.reportsanddata.com/request-customization-form/1233
Thank you for taking the time to read our article. The report can be tailored to the needs of the client. Please contact us for more details, and our team will tailor the report to your specific requirements.
Explore Trending Report:
Deep Vein Thrombosis (DVT) Market – https://www.biospace.com/article/deep-vein-thrombosis-dvt-market-growth-industry-size-trends-and-regional-forecast-to-2030-reports-and-data/
Increasing Number of Clinical Trials Ongoing to Avail Newer and Safer Treatment Options Is Expected to Drive Bronchial Spasm Treatment Market – https://www.biospace.com/article/increasing-number-of-clinical-trials-ongoing-to-avail-newer-and-safer-treatment-options-is-expected-to-drive-bronchial-spasm-treatment-market-growth-by-2030-reports-and-data/
Increased Spending On Healthcare Infrastructure Development Is Expected To Drive Bardet Biedl Syndrome Treatment Market – https://www.biospace.com/article/increased-spending-on-healthcare-infrastructure-development-is-expected-to-drive-bardet-biedl-syndrome-treatment-market-growth-by-2030-reports-and-data/
Increase In New Reported Cases Of Alkaptonuria Is Expected To Drive Alkaptonuria Treatment Market – https://www.biospace.com/article/increase-in-new-reported-cases-of-alkaptonuria-is-expected-to-drive-alkaptonuria-treatment-market-growth-by-2030-reports-and-data/
Increasing Number Of Clinical Trials Ongoing To Avail New And Safe Treatment Options Is Expected To Drive Acute Gout Flare Treatment Market –
Bronchiolitis Market Europe – https://www.reportsanddata.com/report-detail/bronchiolitis-market
Aplastic Anemia Market Latin America – https://www.reportsanddata.com/report-detail/aplastic-anemia-market
Transverse Myelitis Market Size – https://www.reportsanddata.com/report-detail/transverse-myelitis-market
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyse consumer behaviour shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Power and Energy, and Chemicals. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release
Browse Upcoming Reports: https://www.reportsanddata.com/upcoming-reports
Browse Press Release: https://www.reportsanddata.com/press-release/global-dry-powder-inhaler-device-market